SHERP

Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme

Cited 0 time in webofscience Cited 0 time in scopus
Authors
Choi, In Sil; Lee, Se Hoon; Kim, Tae-You; Bang, Jae Seug; Paek, Sun Ha; Kim, Suzy; Kim, Il Han; Heo, Dae Seog; Bang, Yung-Jue; Kim, Dong Gyu; Jung, Hee-Won; Kim, Noe Kyeong
Issue Date
2002
Publisher
Springer Verlag
Citation
J Neurooncol 60: 171-176
Keywords
Antineoplastic Agents/*administration & dosage/adverse effectsBrain Neoplasms/*drug therapy/mortality/radiotherapyCisplatin/*administration & dosage/adverse effectsCombined Modality TherapyGlioblastoma/*drug therapy/mortality/radiotherapyNimustine/*administration & dosage/adverse effectsSurvival Analysis
Abstract
PURPOSE: To evaluate the efficacy and toxicity of chemotherapy with ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-(2-chloroethyl)-3-nitrosourea) plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. PATIENTS AND METHODS: Between August 1999 and July 2001, previously untreated 30 patients with histologically confirmed glioblastoma multiforme were treated. Chemotherapy consisting of up to 2 cycles of 72 h of continuous intravenous infusion of ACNU (40 mg/m2/day) and cisplatin (40 mg/m2/d) was given over a 6-week period. Radiation was begun 6 weeks after the second cycle of chemotherapy. RESULTS: Median age was 48 years (range 18-66 years) and 22 patients with residual measurable disease after surgery were eligible for response analysis. One (5%) had a complete response (CR), 36% partial response (PR), 14% stable disease (SD), and 45% progressive disease (PD) after chemotherapy. After additional radiation, 22% had CR, 22% PR, 16% SD, and 42% PD. Grades III and IV leukopenia and thrombocytopenia occurred in 18 cycles (36%) and 15 cycles (30%), respectively. No fatal complications occurred. Median time to progression was 5.9 months (95% CI 5.1-6.8 months) and median overall survival was 14.9 months (95% CI 9.1-20.7 months). CONCLUSIONS: Preradiation chemotherapy with ACNU plus cisplatin is effective and feasible in patients with gliobiastoma multiforme.
ISSN
0167-594X (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12635665

http://hdl.handle.net/10371/12137
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse